Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

The estimated patent date of Remicade and Rituxan

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
rwdm Member Profile
 
Followed By 2
Posts 74
Boards Moderated 0
Alias Born 07/19/10
160x600 placeholder
The European Parliament overwhelmingly approved a resolution that calls for a possible breakup of Google, brushing aside last-minute objections from the U.S. Congress that the move risked politicizing an antitrust investigation.
More Top Equities Stories Of The Day
Spotify's Revenue Rose in 2013, But Losses Continued - 2nd Update
Telefónica Works to Redraw Its Empire
Canada Resident Caught Up in China Corruption Probe
Correction to La Compagnie Fares Story
Appeals Court Grants TV Programmers Stay in FCC Dispute -- Update
SEC Grants Bank of America Short-Term Waiver from Hedge-Fund Restrictions
Kinder Morgan Unveils $6 Billion Debt Offer -- Update
Deere Projects Sharp Decline in Farm-Equipment Sales -- 2nd Update
rwdm   Thursday, 07/29/10 02:07:10 PM
Re: None
Post # of 184203 
The estimated patent date of Remicade and Rituxan in Europe are 2014 and 2015 respectively. In the US both expiry dates are in 2018. Is this because of Genentech's Cabily patent? If yes, does this mean that the expiry date of most of the mabs in US is 2018?

Is Teva's Rituximab TL011, which is starting nowadays clinical trials, in the regulatory pathway of BLA or as a biosimilar?

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist